
OncoNano Medicine Announces First Patient Dosed in Phase 1 Study Evaluating ONM-501 in Patients with…
OncoNano Medicine Announces First Patient Dosed in Phase 1 Study Evaluating ONM-501 in Patients with…
OncoNano Medicine Announces Promotion of Kartik Krishnan, MD, PhD, to President and Head of Research…
OncoNano Medicine Announces Positive Preclinical Data for ON-BOARD™ IL-12 Program at SITC 2023 Annual Meeting…
OncoNano Medicine to Present Preclinical Data for ON-BOARD™ Platform at the Society for Immunotherapy of…
OncoNano and Regeneron Enter into Clinical Trial Supply Agreement for Use of Libtayo® (cemiplimab) in…
OncoNano Medicine Presents Positive Final Results from Phase 2 Trial of Pegsitacianine in Podium Presentation…
OncoNano Medicine Announces Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting…
OncoNano Presents Compelling Data for ONM-501 and a Novel Tumor Specific Delivery Technology at AACR…
OncoNano Medicine Presents Data from Phase 2 Pegsitacianine Study at Society of Surgical Oncology (SSO)…
Southlake, TX – January 4, 2023 – OncoNano Medicine, Inc. today announced three poster presentations at…
Southlake, TX – January 4, 2023 – OncoNano Medicine, Inc. today announced that its lead clinical…
Clinically validated pH-sensitive nanomedicine platform allows for tumor specific delivery of protein therapeutics and increased…
ONM-501 shown to be promising immuno-therapeutic candidate for clinical evaluation in solid tumors SOUTHLAKE, Texas…
– Interim Phase 2 results presented at World Molecular Imaging Conference 2022 – – Pegsitacianine…
SOUTHLAKE, Texas – September 19, 2022 – OncoNano Medicine, Inc., a clinical-stage biotechnology company focused…
SOUTHLAKE, Texas – September 14, 2022 – OncoNano Medicine, Inc. today announced a presentation of…
– Oncology Development Veteran to Lead the Advancement of OncoNano’s Portfolio SOUTHLAKE, Texas – June…
SOUTHLAKE, Texas – May 10, 2022 – OncoNano Medicine, Inc. today announced the appointment of…
– ONM-501 is a dual-activating polyvalent STING agonist for immuno-oncology applications formulated with OMNI™, the…
SOUTHLAKE, Texas – April 12, 2022 – OncoNano Medicine, Inc. today announced positive results from…
March 10, 2022 SOUTHLAKE, Texas–(BUSINESS WIRE)–OncoNano Medicine, Inc. today announced two poster presentations at the…
-Will convert previous grant awards to an equity investment in OncoNano’s Series B -Additional capital…
Update on pH-sensitive fluorescent nanoprobe from late-breaking oral presentation at The World Molecular Imaging Congress…
OncoNano Medicine Announces Positive Preclinical Data for ONM-501 at AACR Virtual Conference on Tumor Immunology…
OncoNano Medicine to Present at The American Association for Cancer Research Virtual Conference on Tumor…
OncoNano Medicine Announces Expanded Research Collaboration with UT Southwestern Medical Center to Advance Development of…
July 19, 2021 SOUTHLAKE, Texas–(BUSINESS WIRE)–OncoNano Medicine, Inc. today announced a presentation at the 2nd Annual LifeSci…
Financing round led by Advantech healthcare investment team Funds will support Phase 3 program for…
SOUTHLAKE, Texas – August 27, 2019 – OncoNano Medicine, Inc. today announced that it has…
Southlake, TX. – June 26, 2020 – OncoNano Medicine, Inc. announced today the publication of…
– UTSW scientists demonstrate that a novel pH-sensitive polymer prolongs STING-mediated activation of innate immunity against…
OncoNano Medicine | Dallas Web Design By LIFT
Financial Conflict of Interest Policy